Treatment Options After Progression on Frontline Maintenance Therapy

May 13, 2022

By Petros Grivas, MD, PhD
Shilpa Gupta, MD

Video

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.

EP: 1.Recent Treatment Advances in Urothelial Cancer

EP: 2.Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

EP: 3.The Role of Biomarkers in Immunotherapy Selection for mUC

EP: 4.JAVELIN Bladder 101: Study Design and Patient Outcomes

EP: 5.Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

EP: 6.Strategies and Barriers in mUC Maintenance Therapy

EP: 7.Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

EP: 8.Maintenance Therapy Duration and Considerations for Treatment Interruption

Now Viewing

EP: 9.Treatment Options After Progression on Frontline Maintenance Therapy

EP: 10.Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

EP: 11.ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy

EP: 12.ASCO GU 2022 Updates: Antibody-Drug Conjugates

EP: 13.ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

EP: 14.Emerging Data and Future Directions in UC

EP: 15.Recap: Treatment Updates in Urothelial Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!